Top broker says this ASX tech share has over 30% upside

This tech share could have huge upside potential…

| More on:
A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been a disappointing year for the CogState Limited (ASX: CGS) share price.

Since the start of 2022, the neuroscience technology company's shares have tumbled 43% to $1.45.

Is the CogState share price in the buy zone?

One leading broker that believes the CogState share price is great value after this decline is Bell Potter.

According to a note, the broker has retained its buy rating with a slightly trimmed price target of $1.95.

Based on the current CogState share price, this implies potential upside of 34% for investors over the next 12 months.

What did the broker say?

Bell Potter highlights that CogState appears well-placed to benefit from a significant increase in therapies aiming to treat Alzheimer's disease. This increased activity bodes well for demand for the company's brain health assessments. It explained:

With currently no disease modifying therapies (DMT) available, there has been an increasing interest in identifying potential treatments. The number of unique agents under investigation has increased from 93 in 2016 to 143 in 2022. The amyloid hypothesis has been a critical target for these therapies with important Phase 3 trials underway and results on the horizon.

In addition, the broker highlights that CogState has a material revenue backlog and notes that demand is increasing for other indications.

Cogstate currently has US$139.1m in contracted revenue backlog: US$100.2m in clinical trials and US$38.9m in healthcare (EISAI agreement). 84% of new clinical trial contracts in FY22 were in AD which reflects the strong relationship with CGS. Whilst there has been increasing utilisation of CGS technology in other indications such as Parkinson's Disease, Rare Paediatric Disorders and Depression, these studies are usually of lower contract sizes (safety endpoints, smaller cohort sizes).

All in all, the broker believes this will underpin solid sales and earnings growth through to at least FY 2025. In fact, by then, the broker expects CogState's revenue to be $79.8 million and its EBIT to be $18.4 million. This will be a 77.3% and 72% increase, respectively, over FY 2022's numbers.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CogState Limited. The Motley Fool Australia has positions in and has recommended CogState Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Technology Shares

Here are 2 exciting ASX shares rated as buys

These shares are highly rated by brokers. Let's find out why.

Read more »

Two IT professionals walk along a wall of mainframes in a data centre discussing various things
Technology Shares

Is this the decade of the data centre? One ASX 200 stock that could benefit

Let's see why one leading broker thinks this stock could be destined for big things.

Read more »

A human-like robot checks out market performance on a laptop, indicating the rise of AI shares.
Technology Shares

3 top performing ASX AI shares for your watchlist

Have you positioned your portfolio to capitalise on the next tech revolution?

Read more »

A man with a wide, eager smile on his face holds up three fingers.
AI Stocks

3 reasons to buy NextDC shares today

A leading expert forecasts more growth to come for NextDC's rebounding shares.

Read more »

A share market analyst looks at his computer screen in front of him showing ASX share price movements
Technology Shares

Why this $3.9 billion acquisition makes Xero shares a buy today

A leading expert forecasts that Xero’s $3.9 billion investment is about to pay off.

Read more »

Three young people in business attire sit around a desk and discuss.
Small Cap Shares

Tiny tech: 3 ASX small-cap shares with new ratings

Toby Grimm of Baker Young and Peter Day of Sequoia Wealth Management share their new ratings.

Read more »

Smiling young parents with their daughter dream of success.
Technology Shares

Could Life360 shares rise to $37.50?

Bell Potter has given its verdict on this tech stock.

Read more »

Man smiling at a laptop because of a rising share price.
Technology Shares

Investors should put these 2 top ASX tech shares on the watchlist

Looking for growth? These two stocks are delivering.

Read more »